Optimizing use of opiates in the management of cancer pain

Therapeutics and Clinical Risk Management

Volumn 2, Issue 4, 2006, Pages 447-453

  Mandalà, Mario ^a   Moro, Cecilia ^a   Labianca, Roberto ^a   Cremonesi, Marco ^b   Barni, Sandro ^b  

^a OSPEDALI RIUNITI   (Italy)

^b Treviglio Hospital   (Italy)

Author keywords

Cancer patients; Opioids; Pain

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BISACODYL; CISPLATIN; CLONAZEPAM; CORTICOSTEROID; DIAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; FENTANYL; GABAPENTIN; HALOPERIDOL; LACTULOSE; METHADONE; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PHENOLPHTHALEIN; PHENOTHIAZINE; SENNA EXTRACT; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

ADJUVANT THERAPY; AGITATION; CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSENSUS DEVELOPMENT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DISEASE SEVERITY; DROWSINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PAIN ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; STEADY STATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 33845445828     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.4.447     Document Type: Review

References (46)

1. Ahmedzai S, Brooks D. 1997. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage, 13:254-61
2. Ashby MA, Martin P, Jackson KA. 1999. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust, 170:68-71.
3. Battaglia J, Moss S, Rush J, et al. 1997. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double blind, emergency department study. Am J Emerg Med, 15:335-40.
4. Bruera E, MacMillian K, Hanson J, et al. 1989. The cognitive effects of the administration of arcotics analgesics in patients with cancer pain. Pain, 39:13-16.
5. Bruera E, Miller L, McCallion J, et al. 1992. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage, 7:192-5.
6. Bruera E, Palmer JL, Bosnjak S, et al. 2004. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol, 1:185-92.
7. Bruera E, Sweeney C. 2002. Methadone use in cancer patients with pain: a review. J Palliat Med, 5:127-38.
8. Cherny N, Ripamonti C, Pereira J, et al. 2001. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol, 19:2542-54.
9. Cleeland CS, Portenoy RK, Rue M, et al. 2005. Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group. Ann Oncol, 16:972-80.
10. Curtis GB, Johnson GH, Clark P, et al. 1999. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol, 55:425-9.
11. Davis MP, Walsh D, Lagman R, et al. 2005. Controversies in pharmacotherapy of pain management. Lancet Oncol, 6:696-704.
12. De Conno F, Craceni A, Martini C, et al. 1991. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain, 47:337-9.
13. Du Pen SL, Du Pen AR, Polissar N, et al. 1999. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. J Clin Oncol, 17:361-70.
14. Bruera E, Belzile M, Fainsinger R, et al. 1998. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release morphine in patients with cancer pain. J Clin Oncol, 16:3222-9.
15. Davis MP, Walsh D, Lagman R, et al. 2003. Randomized clinical trial of an implantable drug delivery system J Clin Oncol, 21:2800-1.
16. Eisele JH, Grigsby EJ, Dea G, et al. 1992. Clonazepam treatment of myoclonic contractions associated with hidose opioids: case report. Pain, 49:231-2.
17. Elliott K, Minami N, Kolesnikov Y, et al. 1994. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to the kappa opioids. Pain, 56:69-75.
18. Gordon DB, Dahl JL, Miaskowski C, et al. 2005. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med, 165:1574-80.
19. Hanks GW, Conno F, Cherny N, et al. 2001. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer, 84:587-93.
20. Heiskanen T, Kalso E. 1997. Controlled-release oxycodone and morphine in cancer related pain, Pain, 73:37-45.
21. Kalso E, Heiskanen T, Rantio M, et al. 1996. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain, 67:443-9.
22. Kaplan R, Parris WC, Citron ML, et al. 1998. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol, 16:3230-7.
23. Levy MH, Samuel TA. 2005. Management of cancer pain. Semin Oncol, 32:179-93.
24. Maddocks I, Somogyi A, Abbott F, et al. 1996. Attenuation of morphine induced delirium in palliative care by substitution with infusion oxycodone. J Pain Symptom Manage, 12:182-9.
25. Mandema JW, Kaiko RF, Oshlack B, et al. 1996. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol, 42:747-56.
26. McNicol E, Strassels SA, Goudas L, et al. 2005. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev, 2:CD005180.
27. Mercadante S. 1999. Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer, 86:1856-66.
28. Mercadante S, Casuccio A, Agnello A, et al. 1998. Morphine versus methadone in the pain treatment of advanced cancer patients followed up at home. J Clin Oncol, 16:3656-61.
29. Mercadante S, Casaccio A, Fulfaro F, et al. 2001. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol, 19:2898-904.
30. Mucci-LoRusso P, Berman BS, Silberstein PT, et al. 1998. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain. A randomized, double-blind, parallel-group study. Eur J Pain, 2:239-49.
31. Obeso JA. 1995. Therapy of myoclonus. Clin Neurosci, 3:253-7.
32. Paix A, Coleman A, Lees J, et al. 1995. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain, 63:263-9.
33. Pasternak GW. 2005. Molecular biology of opioid analgesia. J Pain Symptom Manage, 29:S2-9.
34. Quigley C. 2006. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev, 2.
35. Riley J, Ross JR, Rutter D, et al. 2006. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Supp Care Cancer, 14:56-64.
36. Ripamonti C, Brunelli C. 2003. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival, J Clin Oncol, 21:2801-2.
37. Ripamonti C, Fagnoni E, Campa T, et al. 2006. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Supp Care Cancer, 14:400-7.
38. Ripamonti C, Groff L, Brunelli C, et al. 1998. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol, 16:3216-21.
39. Ripamonti C, Zecca E, Bruera E. 1997. An update on the clinical use of methadone for cancer pain. Pain, 70:109-15.
40. Salzman RT, Roberts MS, Wild J, et al. 1999. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage, 18:271-9.
41. Sjogren P, Banning A. 1989. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain, 39:5-11.
42. Smith TJ, Coyne PJ, Staats PS, et al. 2005. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol, 16:825-33.
43. Smith TJ, Staats PS, Deer T, et al. 2002. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol, 19:4040-9.
44. Trowbridge R, Dugan W, Jay SJ, et al. 1997. Determining the effectiveness of a clinical-practice intervention in improving the control of pain in outpatients with cancer. Acad Med, 72:798-800.
45. Vainio A, Tigetstedt I. 1988. Opioid treatment for radiating cancer pain: oral administration vs. epidural techniques. Acta Anaesthesiol Scand, 32:179-85.
46. Walsh TD, MacDonald N, Bruera E, et al. 1992. A controlled study of sustained release morphine sulphate tablets in chronic pain from advanced cancer Am J Clin Oncol, 15:268-72.